In compliance with Order S.O. 5690(E) dated 17th October 2026 issued by the National Pharmaceutical Pricing Authority (NPPA), Department of Pharmaceuticals, Government of India, under Paragraph 19 of the Drugs (Prices Control) Order, 2013, the trade margin on specified non-scheduled anti-cancer medicines has been capped at 30%. Accordingly, Naprod Life Sciences Pvt Ltd has reduced the MRP of the following products. The revised MRPs will be effective from 9th November 2026.
| Sl. No | Brand Name | Pack Size | Revised MRP (₹, incl. GST) |
|---|---|---|---|
| 1 | Probira 250 | 120 T | 5,453.34 |
| 2 | Probira 500 | 60 T | 5,614.29 |
| 3 | 4 - Epeedo - 10 | Vial | 230.22 |
| 4 | 4 - Epeedo - 50 | Vial | 675.00 |
| 5 | Everecan 10mg | 10 T | 5,760.81 |
| 6 | Everecan 5 | 10 T | 2,921.06 |
| 7 | Lysilate | Vial | 9,750.00 |
| 8 | Calbitin | Vial | 1,383.75 |
The notice as published. Select an image to open it full size.
The table above lists the revised prices only. The superseded prices appear in the notice itself. Should the table and the published notice differ in any respect, the published notice prevails.